2. Academic Validation
  3. Dostarlimab: First Approval

Dostarlimab: First Approval

  • Drugs. 2021 Jul;81(10):1213-1219. doi: 10.1007/s40265-021-01539-5.
Anthony Markham 1
Affiliations

Affiliation

  • 1 Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. [email protected].
PMID: 34106455 DOI: 10.1007/s40265-021-01539-5
Abstract

Dostarlimab (Jemperli™; GlaxoSmithKline) is a humanized monoclonal antibody programmed death-1 (PD-1) receptor antagonist being developed for the treatment of various cancers. Based on preliminary results from the GARNET trial dostarlimab has recently been approved in the EU and USA for the treatment of adult patients with mismatch repair deficient recurrent or advanced endometrial Cancer. This article summarizes the milestones in the development of dostarlimab leading to these first approvals.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P99827
    Anti-TIM-3 mAb